THE UNIVERSITY OF TEXAS
MD Anderson Cancer Center

Chirag Patel, M.D., Ph.D.

Department of Neuro-Oncology, Division of Cancer Medicine

★★★★★ 4.9/5 53 surveys 17 comments

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

McNair Scholar, McNair Medical Institute at The Robert and Janice McNair Foundation, Houston, TX

Dual/Joint/Adjunct Appointment

Neuroscience Graduate Program Faculty, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS), Houston, TX

Cancer Biology Program Faculty, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS), Houston, TX

Education & Training

Degree-Granting Education

2012 The University of Texas at Houston John P. and Kathrine G. McGovern Medical School, Houston, TX, USA, MD, Medicine

2010 The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA, PHD, Biomedical Sciences

2004 Johns Hopkins University, Baltimore, MD, USA, MSE, Biomedical Engineering

2001 Johns Hopkins University, Baltimore, MD, USA, BS, Biomedical Engineering

Postgraduate Training

2016-2019 Research Fellowship, Multimodal Molecular Imaging, Stanford University School of Medicine, Stanford, CA

2016-2019 Clinical Fellowship, Neuro-Oncology, Stanford University School of Medicine, Stanford, CA

2013-2016 Clinical Residency, Neurology, University of California at Los Angeles David Geffen School of Medicine, Los Angeles, CA

2012-2013 Clinical Internship, Internal Medicine, East Tennessee State University Quillen College of Medicine, Johnson City, TN

Experience & Service

Faculty Academic Appointments

Cancer Biology Program Faculty, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2022 - Present

Neuroscience Graduate Program Faculty, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences (GSBS), Houston, TX, 2022 - Present

Assistant Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present

Clinical Assistant Professor, Department of Neurology and Neurological Sciences, Division of Neuro-Oncology, Stanford University School of Medicine, Stanford, CA, 2019 - 2021

Clinical Assistant Professor, Department of Radiology, Division of Molecular Imaging, Stanford University School of Medicine, Stanford, CA, 2019 - 2021

Clinical Instructor, Department of Neurology and Neurological Sciences, Division of Neuro-Oncology, Stanford University School of Medicine, Stanford, CA, 2019 - 2019

Administrative Appointments/Responsibilities

Fellowship Program Director, Department of Neurology and Neurological Sciences, Division of Neuro-Oncology, Stanford University School of Medicine, Stanford, CA, 2021 - 2021

Resident Education Director, Department of Neurology and Neurological Sciences, Division of Neuro-Oncology, Stanford University School of Medicine, Stanford, CA, 2020 - 2021

Other Professional Positions

Faculty Affiliate, Stanford Artificial Intelligence in Medicine and Imaging (AIMI) Center, Stanford, CA, 2020 - 2021

Associate Member, Stanford Cancer Institute (Cancer Imaging and Early Detection Program), Stanford, CA, 2020 - 2021

Affiliated Faculty Member, Stanford University Wu Tsai Neurosciences Institute, Stanford, CA, 2019 - 2021

Institutional Committee Activities

Member, Admissions Committee, The University of Texas Medical Scientist Training Program (MSTP) at Houston (MD/PhD Program of the University of Texas Health Science Center at Houston & The University of Texas MD Anderson Cancer Center), 2023 - Present

Honors & Awards

2022 - Present McNair Scholar, McNair Medical Institute at The Robert and Janice McNair Foundation

2020	40 Under 40 in Cancer Rising Stars and Emerging Leaders, The Lynx Group, Upstream Partners, Swim Across America, and The National Community Oncology Dispensing Association, Inc. (NCODA)
2019	Young Investigators Forum in Neuro-Oncology, Society for Neuro-Oncology (SNO) and WebMD Professional Independent Medical Education (prIME) Oncology
2019	Theodore Segal Endowed Lecture, University of Louisville School of Medicine
2018	Young Investigator Palatucci Research Award, California Neurology Society
2017	Honors Scholar in Medical Education, Stanford University School of Medicine Teaching and Mentoring Academy
2009	Dee S. and Patricia Osborne Endowed Scholarship in the Neurosciences, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences
2005	Excellence in Medicine Leadership Award, American Medical Association Foundation

Professional Memberships

American Society of Clinical Oncology (ASCO)

Member, 2016 - Present

American Association for Cancer Research (AACR)

Member, 2016 - Present

Society for Neuro-Oncology (SNO)

Member, 2014 - Present

American Academy of Neurology (AAN)

Member, 2010 - Present

American Physician Scientists Association (APSA)

Member, 2005 - Present

Sigma Xi (ΣΞ)

Member, 2005 - Present

IEEE Engineering in Medicine and Biology Society (EMBS)

Member, 1998 - Present

Grant & Contract Support

Date:	2023 - 2024
Title:	Integrated Liquid Biopsy and Advanced MRI-based Monitoring of Diffuse Gliomas
Funding Source:	The University of Texas MD Anderson Cancer Center GBM Moonshot Grant
Role:	Co-Principal Investigator
ID:	N/A
Date:	2022 - 2023
Title:	Developmental Research Project Grant
Funding Source:	The University of Texas MD Anderson Cancer Center Brain Cancer SPORE Grant
Role:	Principal Investigator
Date:	2022 - 2030
Title:	McNair Scholar
Funding Source:	McNair Medical Institute at The Robert and Janice McNair Foundation

Role: Principal Investigator
ID: N/A

Date: 2022 - 2025
Title: AACR-Novocure Career Development Award for Tumor Treating Fields (TTFields) Research
Funding Source: American Association for Cancer Research (AACR)
Role: Principal Investigator
ID: N/A

Date: 2021 - 2023
Title: Clinical Development and Commercialization of [18F]DASA-23, an Imaging Strategy for the Improved Management of Glioblastoma
Funding Source: Stanford SPARK Grant
Role: Co-Principal Investigator
ID: N/A

Date: 2021 - 2022
Title: Neuroscience:Translate Grant
Funding Source: Stanford Wu Tsai Neurosciences Institute
Role: Principal Investigator
ID: N/A

Date: 2020 - 2021
Title: Google Cloud Platform (GCP) Award
Funding Source: Stanford Center for Artificial Intelligence in Medicine and Imaging (AIMI) -
Role: Principal Investigator
ID: N/A

Date: 2019 - 2020
Title: Changes in [18F]DASA-23 PET uptake, a measure of pyruvate kinase M2, from pre- to post-therapy in recurrent glioblastoma: effects on survival
Funding Source: Stanford Chemistry, Engineering & Medicine for Human Health (ChEM-H) Testing Molecular Hypotheses in Human Subjects Seed Grant
Role: Investigator
ID: N/A

Date: 2019 - 2021
Title: Development of Novel Molecular Imaging Agents for Visualization of Cytotoxic T-cells and evaluation of CAR-T cell therapy in preclinical models of glioblastoma
Funding Source: Stanford Chemistry, Engineering & Medicine for Human Health (ChEM-H) Postdocs at the Interface Seed Grant
Role: Co-Principal Investigator
ID: N/A

Date: 2019 - 2021
Title: Extramural Loan Repayment Program for Clinical Researchers (LRP-CR)
Funding Source: NIH
Role: Principal Investigator
ID: N/A

Date: 2017 - 2020
Title: Basic Research Fellowship supported by the Ryan J. Hanrahan Memorial
Funding Source: American Brain Tumor Association
Role: Principal Investigator
ID: BRF1700008

Date: 2017 - 2018
Title: Fellowship Award for Cancer Research
Funding Source: Stanford Cancer Institute
Role: Principal Investigator
ID: N/A

Date: 2016 - 2017
Title: NIH NINDS Research Education Grant (R25) Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, and Neuroradiology
Funding Source: NIH/NINDS
Role: Trainee
ID: 5R25NS065741-07

Date: 2016 - 2018
Title: Stanford Society of Physician Scholars Grant
Funding Source: Stanford University School of Medicine
Role: Co-Principal Investigator
ID: N/A

Date: 2015 - 2016
Title: Research Education Grant (R25) Programs for Residents and Fellows in Neurology, Neurosurgery, Neuropathology, and Neuroradiology
Funding Source: NIH/NINDS
Role: Trainee
ID: 2 R25 NS 065723 06

Date: 2015 - 2016
Title: Research Seed Grant
Funding Source: American Medical Association Foundation
Role: Principal Investigator
ID: N/A

Date: 2009
Title: Research Medical Student Grant
Funding Source: Radiological Society of North America (RSNA)
Role: Principal Investigator
ID: N/A

Date: 2006 - 2008
Title: Ethics in Action Grant
Funding Source: American Medical Association Ethics Group
Role: Co-Principal Investigator
ID: N/A

Date:	2002
Title:	Health Sciences Student Fellowship
Funding Source:	Epilepsy Foundation of America
Role:	Principal Investigator
ID:	N/A

Selected Publications

Peer-Reviewed Articles

1. Abreu M, Patel CB, Patel K, Khawaja F, Tummala S. Progressive Multifocal Encephalopathy in Chimeric Antigen Receptor T-Cell Therapy Recipients: A Case Study. Journal of the Advanced Practitioner in Oncology, 2025.
2. Martinez-Paniagua M, Khan S, Henning NW, Konagalla SV, Patel CB (https://pubmed.ncbi.nlm.nih.gov/39997634/). Optimized Methods to Quantify Tumor Treating Fields (TTFields)-Induced Permeabilization of Glioblastoma Cell Membranes. Methods Protoc 8(1):10, 2025. PMID: 39997634.
3. Amer A, Ansari S, Krayyem A, Kundu S, Khose S, Pokhylevych H, Calle S, Patel CB, Yang Z, Liu HA, Johnson JM (https://pubmed.ncbi.nlm.nih.gov/39876523/). Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma. J Comput Assist Tomogr, 2025. PMID: 39876523.
4. Gregory TA, Knight SR, Aaroe AE, Highsmith KN, Janatpour ZC, O'Brien BJ, Majd NK, Loghin ME, Patel CB, Weathers SP, Puduvalli VK, Kamiya-Matsuoka C (https://doi.org/10.1093/nop/npae029). Accelerated tumor progression after COVID-19 infection in patients with glioblastoma: a retrospective case-control study. Neuro-Oncology Practice:npae029, 2024.
5. Ledbetter D, Almeida R, Wu X, Naveh A, Gonzalez Q, Patel CB, Beckham T, North R, Rhines L, Ghia A, Aten D, Tatsui C, Li J, Alvarez-Breckenridge C. Tumor treating fields suppress tumor cell growth and neurologic decline in models of spine metastases. JCI Insight, 2024.
6. Nguyen H, Schubert KE, Pohling C, Chang E, Yamamoto V, Zeng Y, Nie Y, Van Buskirk S, Schulte RW, Patel CB. Impact of glioma peritumoral edema, tumor size, and tumor location on alternating electric fields (AEF) therapy in realistic 3D rat glioma models: a computational study. Physics in Medicine and Biology, 2024.
7. Tatsui CE, Carlson KW, Patel CB (https://academic.oup.com/noa/advance-article/doi/10.1093/noajnl/vdad170/7505306). Tumor Treating Fields (TTFields) for Spinal Metastasis - the Case for Bone Removal and Spinal Implants as Waveguides to Enhance Field Strength at the Target. Neuro-Oncology Advances, 2024.
8. Beckham TH, Rooney MK, McAleer MF, Ghia AJ, Tom MC, Perni S, McGovern S, Grosshans D, Chung C, Wang C, De B, Swanson T, Paulino A, Jiang W, Ferguson S, Patel CB, Li J, Yeboa DN (https://academic.oup.com/nop/advance-article/doi/10.1093/nop/npae004/7577548). Hypofractionated radiotherapy for glioblastoma: a large institutional retrospective assessment of two approaches. Neuro-Oncology Practice, 2024.
9. Alhusaini S, Naya L, Reddy S, Patel CB. MEK pathway inhibitor-mediated response in BRAF V600-mutant melanoma with brain parenchymal and leptomeningeal metastases. Annals of Neurology, 2024.
10. Wang DH, Fujita Y, Rodríguez Armendáriz AG, Dono A, Shah M, Putluri N, Pichardo-Rojas PS, Patel CB, Huse JT, Zhu JJ, Parker Kerrigan BC, Lang FF, Esquenazi Y, Ballester LY. The Genomic Alterations in Glioblastoma Influence the Levels of CSF Metabolites. Acta Neuropathologica Communications, 2023.
11. Iv M, Naya L, Sanan S, Van Buskirk SL, Nagpal S, Thomas R, Recht L, Patel CB (https://pubmed.ncbi.nlm.nih.gov/37931176/). Tumor Treating Fields Increases Blood-Brain Barrier Permeability and Relative Cerebral Blood Volume in Patients with Glioblastoma. The Neuroradiology Journal, 2023. PMID: 37931176.
12. Yamin G, Tranvinh E, Lanzman BA, Tong E, Hashmi SS, Patel CB, Iv M. ASL- and DSC- Perfusion Metrics Improve Agreement and Confidence in Neuroradiologists' Clinical Interpretations of

Posttreatment High-Grade Glioma Surveillance MRI: An Institutional Experience. AJNR Am J Neuroradiol, 2023.

13. Nguyen H, Schubert KE, Chang E, Nie Y, Pohling C, Van Buskirk S, Yamamoto V, Zeng Y, Schulte RW, Patel CB (https://pubmed.ncbi.nlm.nih.gov/37703902/). Electric field distributions in realistic 3D rat head models during alternating electric field (AEF) therapy: a computational study. Physics in Medicine and Biology 68(20), 2023. PMID: 37703902.
14. Pohling C, Nguyen H, Chang E, Schubert KE, Nie Y, Bashkirov V, Yamamoto V, Zeng Y, Stupp R, Schulte RW, **Patel CB** (https://pubmed.ncbi.nlm.nih.gov/36306728/). Current status of the preclinical evaluation of alternating electric fields as a form of cancer therapy. *Bioelectrochemistry* 149, 2023. PMID: 36306728.
15. Xiao D, Yan C, Li D, Xi T, Liu X, Zhu D, Huang G, Xu J, He Z, Wu A, Ma C, Long J, Shu K, Ji H, Wang N, Chen G, Yang J, Ma H, Li Z, Sun X, Qu Y, Liu Z, Jiang X, Tian C, Ni S, Zhan R, Chen L, Ge M, Wang M, Jiang X, Guo G, Han Z, Zhang C, Zhang T, Dou C, Chu L, Wang P, Shao J, Wu X, Yu J, Wang Y, Wu N, Zhang R, Zhang M, Hong Y, Gao J, Li Y, Pan Y, Zhao B, Ji N, Shan G, Patel CB, Jia W, Zhang L (https://pubmed.ncbi.nlm.nih.gov/37283963/). National Brain Tumor Registry of China (NBTRC) Statistical Report of Primary Brain Tumors Diagnosed in China in years 2019-2020. The Lancet Regional Health - Western Pacific 34, 2023. PMID: 37283963.
16. Wu A, Huang RJ, Ruiz Colón G, Zembrzuski K, **Patel CB** (https://pubmed.ncbi.nlm.nih.gov/36419072/). Low Rates of Structured Advance Care Planning Documentation in Electronic Health Records: Results of a Single-Center Observational Study. *BMC Palliative Care* 21(1), 2022. PMID: 36419072.
17. Ceran Y, Ergüder H, Ladner K, Korenfeld S, Deniz K, Padmanabhan S, Wong P, Baday M, Pengo T, Lou E, **Patel CB** (https://pubmed.ncbi.nlm.nih.gov/36230881/). TNTdetect.AI: A deep learning model for automated detection and counting of tunneling nanotubes in microscopy images. *Cancers*, 2022. PMID: 36230881.
18. Shams S, Patel CB (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=35973687). Anti-cancer mechanisms of action of therapeutic alternating electric fields (tumor treating fields [TTFields]). J Mol Cell Biol, 2022. PMID: 35973687.
19. Arami H, Kananian S, Khalifehzadeh L, **Patel CB**, Chang E, Tanabe Y, Zeng Y, Madsen SJ, Mandella MJ, Natarajan A, Peterson EE, Sinclair R, Poon ASY, Gambhir SS (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=35995855). Remotely controlled near-infrared-triggered photothermal treatment of brain tumours in freely behaving mice using gold nanostar?s. *Nat Nanotechnol*, 2022. PMID: 35995855.
20. Sahan AZ, Baday M, **Patel CB** (https://pubmed.ncbi.nlm.nih.gov/36005097/). Biomimetic Hydrogels in the Study of Cancer Mechanobiology: Overview, Biomedical Applications, and Future Perspectives. *Gels* 8(8):496, 2022. PMID: 36005097.
21. Moser JC, Salvador E, Deniz K, Swanson K, Tusynski J, Carlson KW, Karanam NK, *Patel CB*, Story M, Lou E, Hagemann C (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=35839284). The mechanisms of action of Tumor Treating Fields. *Cancer Res*, 2022. PMID: 35839284.
22. Reveron-Thornton R, Scott BJ, Post D, Caulfield AF, Werbaneth K, Hovsepian DA, Spiegel J, Miklos D, Thomas RP, **Patel CB** (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=34950390). Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy. *Neurohospitalist* 12(1):74-79, 2022. e-Pub 2021. PMID: 34950390.
23. Beinat C, **Patel CB**, Haywood T, Murty S, Naya L, Castillo JB, Reyes ST, Phillips M, Buccino P, Shen B, Park JH, Koran MEI, Alam IS, James ML, Holley D, Halbert K, Gandhi H, He JQ, Granucci M, Johnson E, Liu DD, Uchida N, Sinha R, Chu P, Born DE, Warnock GI, Weissman I, Hayden-Gephart M, Khalighi M, Massoud TF, Iagaru A, Davidzon G, Thomas R, Nagpal S, Recht LD, Gambhir SS (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=34475101). A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2-

Induced Glycolytic Reprogramming in Glioblastoma. *Clin Cancer Res* 27(23):6467-6478, 2021. e-Pub 2021. PMID: 34475101.

24. Wu A, Ruiz Colón G, Aslakson R, Pollom E, **Patel CB** (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=34201260). Palliative Care Service Utilization and Advance Care Planning for Adult Glioblastoma Patients: A Systematic Review. *Cancers (Basel)* 13(12), 2021. e-Pub 2021. PMID: 34201260.
25. Kim KM, Tercan S, Baday M, Mahaney KB, Recht LD, Rajadas J, **Patel CB** (https://doi.org/10.1109/NER49283.2021.9441074). Electrophysiological Characterization of Glioma using a Biomimetic Spheroid Model. *Proceedings of the 10th International IEEE/EMBS Conference on Neural Engineering (NER)*:86-89, 2021.
26. Aguilar AA, Ho MC, Chang E, Carlson KW, Natarajan A, Marciano T, Bomzon Z, **Patel CB** (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=34068775). Permeabilizing Cell Membranes with Electric Fields. *Cancers (Basel)* 13(9), 2021. e-Pub 2021. PMID: 34068775.
27. Dono A, Mitra S, Shah M, Takayasu T, Zhu JJ, Tandon N, **Patel CB**, Esquenazi Y, Ballester LY (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=33881725). PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma. *J Neurooncol* 153(1):153-160, 2021. e-Pub 2021. PMID: 33881725.
28. **Patel CB**, Beinat C, Xie Y, Chang E, Gambhir SS (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=33221711). Tumor treating fields (TTFields) impairs aberrant glycolysis in glioblastoma as evaluated by [18F]DASA-23, a non-invasive probe of pyruvate kinase M2 (PKM2) expression. *Neoplasia* 23(1):58-67, 2021. e-Pub 2020. PMID: 33221711.
29. Zhou Q, van den Berg NS, Rosenthal EL, Iv M, Zhang M, Vega Leonel JCM, Walters S, Nishio N, Granucci M, Raymundo R, Yi G, Vogel H, Cayrol R, Lee YJ, Lu G, Hom M, Kang W, Hayden Gephart M, Recht L, Nagpal S, Thomas R, **Patel C**, Grant GA, Li G (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=34158840). EGFR-targeted intraoperative fluorescence imaging detects high-grade glioma with panitumumab-IRDye800 in a phase 1 clinical trial. *Theranostics* 11(15):7130-7143, 2021. e-Pub 2021. PMID: 34158840.
30. Beinat C, **Patel CB**, Haywood T, Shen B, Naya L, Gandhi H, Holley D, Khalighi M, Iagaru A, Davidzon G, Gambhir SS (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=31938892). Human biodistribution and radiation dosimetry of [18F]DASA-23, a PET probe targeting pyruvate kinase M2. *Eur J Nucl Med Mol Imaging* 47(9):2123-2130, 2020. e-Pub 2020. PMID: 31938892.
31. Sun J, **Patel CB**, Jang T, Merchant M, Chen C, Kazerounian S, Diers AR, Kiebish MA, Vishnudas VK, Gesta S, Sarangarajan R, Narain NR, Nagpal S, Recht L (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&api_key=f0c738c0db4332ade5c06586e736cfd0d508&list_uids=32807842). High levels of ubidecarenone (oxidized CoQ10) delivered using a drug-lipid conjugate nanodispersion (BPM31510) differentially affect redox status and growth in malignant glioma versus non-tumor cells. *Sci Rep* 10(1):13899, 2020. e-Pub 2020. PMID: 32807842.

Patient Reviews

★★★★★ 4.9/5 **Overall Rating (53 reviews)** Understand Star Ratings

1.
★★★★★5/5
Listened Carefully to You

2.
★★★★★4.8/5
Explanations Easy to Understand

3.
★★★★★4.9/5
Knew Your Medical History

4.
★★★★★5/5
Gave Easy to Understand Instructions

5.
★★★★★4.9/5
Spent Enough Time With You

6.
★★★★★4.9/5
Showed Respect for You

7.
★★★★★4.9/5
Would Recommend Provider's Office

8.
★★★★★4.9/5
Provider Rating 0 - 10

Comments (17)

My provider was perfect. He understood me. He took his time with me. He was friendly. It was a very great experience. Thank you.

Excellent experience Thank you

Dr. Patel was very through in his explanations and answered every question that I had. He spent adequate time with me and I never felt he was in a rush. I was impressed that he had read My Chart questions/concerns that I had submitted to my primary oncologist.

This provider was the most through doctor I have seen at MDA. His answers and explanations were easy to understand and relevant. He was prepared with prior medical history through MyChart. His approach was refreshing and the time spent with him was valuable.

★★★★★
I received excellent care and they were very friendly.

★★★★★
Dr Patel was very thorough in explaining exam results in detail and in a way I could comprehend, very didactic showing pictures which was very nice. He was also honest and direct which I appreciate it!

★★★★★
Dr. Patel was very didactic in his explanation of my exam results and the situation I'm in. And he was very thorough in his explanation and very honest and very direct and very straight to the point on what everything meant. He showed me pictures, he explained the functions... continue reading

---

★★★★★
With this provider, I understand my medical information and I learn how to take care of my issues and problems in advance instead of waiting for it to happen. It's a wonderful experience and I highly recommend it.

★★★★★
Dr. Patel has a good relationship with individual patients

★★★★★
Great

★★★★★
Every care professional I interacted with during my appointment was great. I walked away feeling very good about the visit, the information provided, and the exchange over all. Keep up the great work!!!

★★★★★
Excellent team!!! Very attentive and comfortable.

★★★★★
All of the people on the 7th floor brain and spine unit are very good!

★★★★☆
Very understanding

★★★★★
All I can say is wonderful

★★★★★
Outstanding team of technicians!!!

★★★★★
Very,very impressed with his knowledge, professionalism and kind attitude.
